Siegel RL, Miller KD. Cancer statistics. Cancer J Clin. 2022;72(1):7–33.

Article  Google Scholar 

Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387(10021):894–906.

Article  PubMed  Google Scholar 

Kasherman L, Siu DHW. Angiogenesis inhibitors and immunomodulation in renal cell cancers: the past, present, and future. Cancers. 2022;14(6):1406\[‘.

Article  PubMed  Google Scholar 

Ballesteros P, Chamorro J, Román-Gil MS. Molecular mechanisms of resistance to immunotherapy and antiangiogenic treatments in clear cell renal cell carcinoma. Cancers. 2021;13(23):5981.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang N, Pati D. Sororin is a master regulator of sister chromatid cohesion and separation. Cell Cycle. 2012;11(11):2073–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jordan PW, Eyster C, Chen J, Pezza RJ, Rankin S. Sororin is enriched at the central region of synapsed meiotic chromosomes. Chrom Res. 2017;25(2):115–28.

Article  CAS  PubMed  Google Scholar 

Chong Y, Xue L. Downregulation of CDCA5 Can inhibit cell proliferation, migration, and invasion, and induce apoptosis of prostate cancer cells. Crit Rev Eukaryot Gene Expr. 2021;31(1):29–40.

Article  PubMed  Google Scholar 

Fu G, Xu Z, Chen X, Pan H, Wang Y, Jin B. CDCA5 functions as a tumor promoter in bladder cancer by dysregulating mitochondria-mediated apoptosis, cell cycle regulation and PI3k/AKT/mTOR pathway activation. J Cancer. 2020;11(9):2408–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shen W, Tong D, Chen J, Li H, Hu Z, Xu S, He S, Ge Z, Zhang J, Mao Q, Chen H, Xu G. Silencing oncogene cell division cycle associated 5 induces apoptosis and G1 phase arrest of non-small cell lung cancer cells via p53–p21 signaling pathway. J Clin Lab Analy. 2022;36(5):e24396.

Article  CAS  Google Scholar 

Hou S, Chen X, Li M, Huang X, Liao H, Tian B. Higher expression of cell division cycle-associated protein 5 predicts poorer survival outcomes in hepatocellular carcinoma. Aging. 2020;12(14):14542–55.

Article  PubMed  PubMed Central  Google Scholar 

Shen A, Liu L, Chen H, Qi F, Huang Y, Lin J, Sferra TJ, Sankararaman S, Wei L, Chu J, Chen Y, Peng J. Cell division cycle associated 5 promotes colorectal cancer progression by activating the ERK signaling pathway. Oncogenesis. 2019;8(3):19.

Article  PubMed  PubMed Central  Google Scholar 

Jin X, Wang D, Lei M, Guo Y, Cui Y, Chen F, Sun W, Chen X. TPI1 activates the PI3K/AKT/mTOR signaling pathway to induce breast cancer progression by stabilizing CDCA5. J Translat Med. 2022;20(1):191.

Article  CAS  Google Scholar 

Xu J, Zhu C, Yu Y, Wu W, Cao J, Li Z, Dai J, Wang C, Tang Y, Zhu Q, Wang J, Wen W, Xue L, Zhen F, Liu J, Huang C, Zhao F, Zhou Y, He Z, Pan X, Wei H, Zhu Y, He Y, Que J, Luo J, Chen L, Wang W. Systematic cancer-testis gene expression analysis identified CDCA5 as a potential therapeutic target in esophageal squamous cell carcinoma. EBioMedicine. 2019;46:54–65.

Article  PubMed  PubMed Central  Google Scholar 

Lopez J, Tait SW. Mitochondrial apoptosis: killing cancer using the enemy within. Br J Cancer. 2015;112(6):957–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jin J, Xie Y, Zhang JS, Wang JQ, Dai SJ, He WF, Li SY, Ashby CR Jr, Chen ZS, He Q. Sunitinib resistance in renal cell carcinoma: from molecular mechanisms to predictive biomarkers. Drug Resist Updat. 2023;67: 100929.

Article  CAS  PubMed  Google Scholar 

Kariri YA, Joseph C. Mechanistic and clinical evidence supports a key role for cell division cycle associated 5 (CDCA5) as an independent predictor of outcome in invasive breast cancer. Cancers. 2022;14(22):5643.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu GY, Sabatini DM. mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Bio. 2020;21(4):183–203.

Article  CAS  Google Scholar 

Serzan MT, Atkins MB. Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma. J Cancer Metastasis Treat. 2021;7:39.

CAS  PubMed  PubMed Central  Google Scholar 

Bosma NA, Warkentin MT, Gan CL, Karim S, Heng DYC, Brenner DR, Lee-Ying RM. Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Open Sci. 2022;37:14–26.

Article  PubMed  PubMed Central  Google Scholar 

Kim MC, Jin Z, Kolb R, Borcherding N, Chatzkel JA, Falzarano SM. Updates on immunotherapy and immune landscape in renal clear cell carcinoma. Cancers. 2021;13(22):5856.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McKay RR, Bossé D, Choueiri TK. Evolving systemic treatment landscape for patients with advanced renal cell carcinoma. J Clin Oncol. 2018. https://doi.org/10.1200/JCO.2018.79.0253.

Article  PubMed  Google Scholar 

Boeynaems S, Tompa P, Van Den Bosch L. Phasing in on the cell cycle. Cell Div. 2018;13:1.

Article  PubMed  PubMed Central  Google Scholar 

López-Lázaro M. The stem cell division theory of cancer. Crit Rev Oncol Hematol. 2018;123:95–113.

Article  PubMed  Google Scholar 

Yoshida K, Yokoi A. Aberrant activation of cell-cycle-related kinases and the potential therapeutic impact of PLK1 or CHEK1 inhibition in uterine leiomyosarcoma. Clin Cancer Res. 2022;28(10):2147–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang Y, Zhang S, Guo L. Characterization of cell cycle-related competing endogenous RNAs using robust rank aggregation as prognostic biomarker in lung adenocarcinoma. Clin Cancer Res. 2022;12: 807367.

CAS  Google Scholar 

Chen H, Chen J, Zhao L, Song W, Xuan Z, Chen J, Li Z, Song G, Hong L, Song P, Zheng S. CDCA5, transcribed by E2F1, promotes oncogenesis by enhancing cell proliferation and inhibiting apoptosis via the AKT pathway in hepatocellular carcinoma. J Cancer. 2019;10(8):1846–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ji J, Shen T, Li Y, Liu Y, Shang Z, Niu Y. CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway. Oncol Rep. 2021;45(3):921–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang Z, Zhang S, Du J, Zhang X, Zhang W, Huang Z, Ouyang P. Cyclin-dependent kinase 1 (CDK1) is co-expressed with CDCA5: their functions in gastric cancer cell line MGC-803. Med Sci Monit. 2020;26: e923664.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chakraborty S, Balan M, Sabarwal A, Choueiri TK, Pal S. Metabolic reprogramming in renal cancer: events of a metabolic disease. Biochim Biophys Acta Rev Cancer. 2021;1876(1): 188559.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wettersten HI, Aboud OA, Lara PN Jr, Weiss RH. Metabolic reprogramming in clear cell renal cell carcinoma. Nat Rev Nephrol. 2017;13(7):410–9.

Article  CAS  PubMed  Google Scholar 

di Meo NA, Lasorsa F, Rutigliano M, Milella M, Ferro M, Battaglia M. The dark side of lipid metabolism in prostate and renal carcinoma: novel insights into molecular diagnostic and biomarker discovery. Expert Rev Mol Diagn. 2023;23(4):297–313.

Article  PubMed  Google Scholar 

Lucarelli G, Loizzo D, Franzin R, Battaglia S, Ferro M, Cantiello F, Castellano G, Bettocchi C, Ditonno P, Battaglia M. Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma. Expert Rev Mol Diagn. 2019;19(5):397–407.

Article  CAS  PubMed  Google Scholar 

di Meo NA, Lasorsa F, Rutigliano M, Loizzo D, Ferro M. Renal cell carcinoma as a metabolic disease: an update on main pathways, potential biomarkers, and therapeutic targets. J Mol Sci. 2022;23(22):14360.

Article  Google Scholar 

De Marco S, Torsello B, Minutiello E, Morabito I, Grasselli C, Bombelli S, Zucchini N, Lucarelli G, Strada G, Perego RA, Bianchi C. The cross-talk between Abl2 tyrosine kinase and TGFβ1 signalling modulates the invasion of clear cell renal cell carcinoma cells. FEBS Lett. 2023;597(8):1098–113.

Article  PubMed  Google Scholar 

Bianchi C, Meregalli C, Bombelli S, Di Stefano V, Salerno F, Torsello B, De Marco S, Bovo G, Cifola I, Mangano E, Battaglia C, Strada G, Lucarelli G, Weiss RH, Perego RA. The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation. Oncotarget. 2017;8(69):113502–15.

Article  PubMed  PubMed Central  Google Scholar 

Ragone R, Sallustio F. Renal cell carcinoma: a study through NMR-based metabolomics combined with transcriptomics. Diseases. 2016;4(1):7.

Article  PubMed